Aptevo Therapeutics Inc.

3.88-0.1300-3.24%Vol 50.75K1Y Perf -83.69%
Jun 24th, 2022 16:00 DELAYED
BID3.75 ASK3.95
Open4.02 Previous Close4.01
Pre-Market- After-Market3.80
 - -  -0.08 -2.06%
Target Price
28.00 
Analyst Rating
Strong Buy 1.00
Potential %
621.65 
Finscreener Ranking
+     37.81
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     30.48
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
     26.61
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
3.85 
Earnings Rating
Sell
Market Cap19.43M 
Earnings Date
11th Aug 2022
Alpha-0.00 Standard Deviation0.78
Beta6.33 

Today's Price Range

3.824.10

52W Range

3.0325.13

5 Year PE Ratio Range

-1.2022.70

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
11.49%
1 Month
-19.83%
3 Months
-36.08%
6 Months
-50.70%
1 Year
-83.69%
3 Years
340.91%
5 Years
69.43%
10 Years
-

TickerPriceChg.Chg.%
APVO3.88-0.1300-3.24
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
1.60
1.70
0.81
13.75
-
Leverage Ratio 15.00
ProfitabilityValueIndustryS&P 500US Markets
82.60
-155.00
-146.60
-329.90
-68.62
RevenueValueIndustryS&P 500US Markets
12.99M
2.59
-28.67
-23.90
Earnings HistoryEstimateReportedSurprise %
Q01 2022-1.15-1.59-38.26
Q03 2021-1.48-1.452.03
Q02 2021-1.95-1.788.72
Q01 2021-1.62-1.74-7.41
Q03 2020-2.05-2.15-4.88
Q02 2020-2.27-2.107.49
Q01 2020-2.55-2.425.10
Q03 2019-3.36-3.224.17
Earnings Per EndEstimateRevision %Trend
6/2022 QR-1.330.00-
9/2022 QR-1.352.17Positive
12/2022 FY-6.24-15.56Negative
12/2023 FY-5.47-16.14Negative
Next Report Date11th Aug 2022
Estimated EPS Next Report-1.33
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume50.75K
Shares Outstanding5.01K
Shares Float4.96M
Trades Count301
Dollar Volume199.80K
Avg. Volume138.09K
Avg. Weekly Volume70.77K
Avg. Monthly Volume126.88K
Avg. Quarterly Volume216.63K

Aptevo Therapeutics Inc. (NASDAQ: APVO) stock closed at 3.88 per share at the end of the most recent trading day (a -3.24% change compared to the prior day closing price) with a volume of 50.75K shares and market capitalization of 19.43M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 80 people. Aptevo Therapeutics Inc. CEO is Marvin L. White.

The one-year performance of Aptevo Therapeutics Inc. stock is -83.69%, while year-to-date (YTD) performance is -50.7%. APVO stock has a five-year performance of 69.43%. Its 52-week range is between 3.03 and 25.1326, which gives APVO stock a 52-week price range ratio of 3.85%

Aptevo Therapeutics Inc. currently has a PE ratio of -0.60, a price-to-book (PB) ratio of 19.27, a price-to-sale (PS) ratio of 1.34, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -52.49%, a ROC of -211.02% and a ROE of -1 432.45%. The company’s profit margin is -68.62%, its EBITDA margin is -146.60%, and its revenue ttm is $12.99 Million , which makes it $2.59 revenue per share.

Of the last four earnings reports from Aptevo Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.33 for the next earnings report. Aptevo Therapeutics Inc.’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for Aptevo Therapeutics Inc. is Strong Buy (1), with a target price of $28, which is +621.65% compared to the current price. The earnings rating for Aptevo Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aptevo Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aptevo Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.39, ATR14 : 0.47, CCI20 : -38.34, Chaikin Money Flow : -0.48, MACD : -0.26, Money Flow Index : 15.69, ROC : -29.71, RSI : 44.41, STOCH (14,3) : 24.36, STOCH RSI : 0.86, UO : 51.92, Williams %R : -75.64), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aptevo Therapeutics Inc. in the last 12-months were: Barbara Lopez Kunz (Option Excercise at a value of $0), Daniel J. Abdun-Nabi (Option Excercise at a value of $0), Grady Grant (Option Excercise at a value of $0), Jeffrey G. Lamothe (Option Excercise at a value of $0), Marvin L. White (Option Excercise at a value of $0), So Young Kwon (Option Excercise at a value of $0), Zsolt Harsanyi (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a biosciences company. The company is engaged in the discovery, development, commercialization and sale of novel oncology and hematology therapeutics. Its pipeline product includes Otlertuzumab, APVO414, Multiple ADAPTIR Candidates, ALG.APV-527, APVO436 and APVO210.

CEO: Marvin L. White

Telephone: +1 206 838-0500

Address: 2401 4th Avenue, Seattle 98121, WA, US

Number of employees: 80

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

79%21%

Bearish Bullish

57%43%

News

Stocktwits